US clearance for wound debridement device:
This article was originally published in Clinica
HydroCision has received US FDA 510(k) clearance for its rapid, fluidjet-based wound debridement system. TraumaJet can be used to remove contamination, such as dirt and grease, from a traumatic wound as well as dead or damaged tissue. The system creates its own suction at the site without the need for a connection to an external source and minimises the risk of spreading bacteria or contamination further into a wound said the Andover, Massachusetts-based company. The system will be marketed worldwide by Orthofix International.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.